Teva Pharmaceutical Industries Ltd.’s proposal to resolve US opioid litigation with free opioid addiction treatment is facing opposition from a new front as members of Congress express concern that the plan could disrupt drug supply from other manufacturers. And in an unusual move, they are attempting to get the US Food and Drug Administration to weigh in on the plan.
Reps. David McKinley, R-WV, and Marcy Kaptur, D-Ohio, sent a 17 August letter to FDA commissioner Stephen Hahn nearly...